New Delhi, March 21 (NationPress) The pharmaceutical sector in India has matured into a globally connected and policy-driven framework, achieving a remarkable position as the third largest in the world by volume and 11th by value. This growth is supported by over 3,000 companies and 10,500 manufacturing facilities, as indicated in an official factsheet released on Saturday.

Currently, the domestic pharmaceutical market is valued at $60 billion and is anticipated to soar to $130 billion by 2030.

The Economic Survey for 2025-26 reports that in FY25, the sector's annual turnover hit Rs. 4.72 lakh crore, with exports growing at a compound annual growth rate (CAGR) of 7 percent over the last decade (FY15 to FY25).

India stands as the largest worldwide provider of generic medications, contributing roughly 20 percent to global supply and producing around 60,000 generic brands across 60 therapeutic categories, as per the factsheet.

Robust manufacturing capabilities, increasing exports, rising foreign investments, and targeted government initiatives have collectively bolstered domestic production, minimized import reliance, and enhanced the global market footprint.

Additionally, programs aimed at fostering affordable access, promoting innovation, ensuring quality, and maintaining regulatory oversight have significantly improved public health outcomes and international trust.

Furthermore, recently finalized trade agreements with the European Union, the United Kingdom, and New Zealand are projected to further bolster India’s pharmaceutical and medical device sectors.

These agreements aim to broaden market access and strengthen India’s global trade connections in the sector. Together, these factors position India’s pharmaceutical industry on a steady, forward-thinking path, fostering sustained growth, global engagement, and long-term resilience,” the factsheet noted.

It is noteworthy that India has the highest number of manufacturing facilities approved by the United States Food and Drug Administration (USFDA) outside the USA, reinforcing global confidence in the safety and quality of Indian pharmaceuticals.

With approximately 500 active pharmaceutical ingredient (API) manufacturers, India accounts for nearly 8 percent of the worldwide API market.

India also leads globally in the supply of Diphtheria, Tetanus, and Pertussis (DPT), Bacillus Calmette-Guerin (BCG), and measles vaccines.

Indian manufacturers supply around 60 percent of vaccine needs for the United Nations International Children’s Emergency Fund (UNICEF), meet 40-70 percent of global demand for DPT and BCG vaccines, and fulfill 90 percent of the World Health Organization’s (WHO) measles vaccine requirements.

This underscores the strength of Indian pharmaceutical exports and their significant integration within international healthcare supply chains.

In the fiscal year 2024-25, pharmaceutical exports reached $30.5 billion, marking a nearly 16-fold increase from $1.9 billion in 2000-01.